News: Research and development

View:
 

Found press releases

 

Michael Oredsson to leave Probi – Gun-Britt Fransson new interim CEO

5/24/2013 2:45 AM EST  -   Probi
Michael Oredsson will leave as CEO of Probi to take up a position as CEO at listed pharmaceutical company BioInvent. Probi’s VP R&D Gun-Britt Fransson has been appointed interim CEO. Michael Oredsson will remain at the disposal of Probi  until he takes up his new position.

”The Board wants to thank Michael for an excllent contribution since he joined the company in 2007. Under Michaels leadership, Probi’s revenue...

First patient dosed in the Phase I/II study of Umecrine Mood’s candidate drug fo...

5/23/2013 2:00 AM EST  -   Karolinska Development AB (publ)
STOCKHOLM – May 23, 2013. Umecrine Mood AB announced today that dosing has been initiated in a randomized Phase I/II study of UC1010 for the treatment of patients with premenstrual dysphoric disorder (PMDD). Umecrine Mood is part of the Karolinska Development portfolio.
Most women experience some form of symptoms the days before menstruation but in about five percent of young and middle-aged women, the symptoms...
Jane Asher meeting KASPAR with Professor Quintin McKellar and Professor Kerstin Dautenhahn
 

Jane Asher supporting autism research in Hertfordshire

5/22/2013 10:13 AM EST  -   University of Hertfordshire
Actress and author Jane Asher, President of the National Autistic Society and Patron of TRACKS Autism, gave the key note presentation at the University of Hertfordshire’s Supporting Children with Autism Healthcare Forum 2013.
The forum, opened by Professor Quintin McKellar, Vice Chancellor at the University of Hertfordshire, brought together over 150 people who have an interest in supporting children with...

Primary efficacy and safety findings from phase III study of Simeprevir in treat...

5/21/2013 8:15 AM EST  -   Medivir
Stockholm, Sweden — Medivir AB (OMX: MVIR) reports that its partner Janssen R&D Ireland (Janssen) today announced primary efficacy and safety results from the global phase III PROMISE study. Results demonstrated that use of the investigational protease inhibitor simeprevir (TMC435) led to sustained virologic response 12 weeks after the end of treatment (SVR12) in 79 percent of treatment-experienced genotype 1...

Positive results from a phase Ia study with MIV-711 for the treatment of skeleta...

5/21/2013 7:00 AM EST  -   Medivir

· Single doses of MIV-711 were safe and well tolerated in healthy subjects and displayed linear pharmacokinetics over the investigated dose range (20 – 600 mg)
· Serum levels of the bone resorption biomarker CTX-I were suppressed in a dose dependent manner) with up to 79% reduction at 24 hours after dose

Stockholm, Sweden – Medivir AB (OMX:MVIR) announced that data from a first in man study on the...
Ann-Mari Svennerholm
 

Researchers develop new oral diarrhea vaccine

5/21/2013 4:00 AM EST  -   Sahlgrenska akademin vid Göteborgs universitet
University of Gothenburg Vaccine Research Institute (GUVAX) announces successful results in a placebo controlled phase I study of an oral, inactivated Escherichia coli diarrhea vaccine.
Enterotoxigenic Escherichia coli (ETEC) bacteria are the primary cause of diarrhea in children living in low and middle income countries result in 400 million diarrheal episodes and approximately 300 000 deaths among children...

Chairman increases holdings in Diamyd

5/17/2013 11:23 AM EST  -   Diamyd Medical AB
The Chairman of Diamyd Medical, Anders Essen-Möller, has today bought 1,429,656 shares in Diamyd Medical and his holdings in Diamyd Medical amounts after the transaction to 479,292 series A-shares and 1,617,397 series B-shares, representing approximately 21% of the capital and about 45% of the votes.

Report from the extra general meeting

5/17/2013 3:52 AM EST  -   ChronTech Pharma AB
At the extra general meeting (EGM) in ChronTech Pharma AB (below ”the Company”) on the 16th of May it was resolved to accept the board’s proposal for restructuring of the company and transfer of the Company’s projects regarding development of DNA-vaccines against hepatitis B and hepatitis C in accordance with the Term Sheet, which was put forward at the EGM and which earlier has been attached to the notice for the...

New Diamyd Medical listed on NASDAQ OMX First North on May 20, 2013

5/15/2013 11:35 AM EST  -   Diamyd Medical AB
Diabetes has developed into a major global problem. The disorder is affecting younger and younger people and complications related to diabetes are currently among the most common causes of death in many countries. In conjunction with the spin-out of the new Diamyd Medical from the Parent Company in April 2013, a dedicated diabetes company was formed. The company will now be listed on NASDAQ OMX First North and the...

Karolinska Development´s Annual General Meeting 2013

5/15/2013 2:00 AM EST  -   Karolinska Development AB (publ)
STOCKHOLM - May 15, 2013. At the Annual General Meeting of Karolinska Development AB held May 14, 2013, the following resolutions were passed, in accordance with the presented proposals:
Profit and loss statement: It was resolved to adopt the profit and loss statement and the balance sheet and the consolidated profit and loss statement and the consolidated balance sheet.

Appropriation of the result: It was...